JP2013515739A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515739A5
JP2013515739A5 JP2012546185A JP2012546185A JP2013515739A5 JP 2013515739 A5 JP2013515739 A5 JP 2013515739A5 JP 2012546185 A JP2012546185 A JP 2012546185A JP 2012546185 A JP2012546185 A JP 2012546185A JP 2013515739 A5 JP2013515739 A5 JP 2013515739A5
Authority
JP
Japan
Prior art keywords
composition
rhodostomin variant
subject
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546185A
Other languages
English (en)
Japanese (ja)
Other versions
JP5739908B2 (ja
JP2013515739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061738 external-priority patent/WO2011079175A1/en
Publication of JP2013515739A publication Critical patent/JP2013515739A/ja
Publication of JP2013515739A5 publication Critical patent/JP2013515739A5/ja
Application granted granted Critical
Publication of JP5739908B2 publication Critical patent/JP5739908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546185A 2009-12-23 2010-12-22 血管形成関連の眼疾患の処置のための組成物および方法 Expired - Fee Related JP5739908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23
US61/289,624 2009-12-23
PCT/US2010/061738 WO2011079175A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Publications (3)

Publication Number Publication Date
JP2013515739A JP2013515739A (ja) 2013-05-09
JP2013515739A5 true JP2013515739A5 (enExample) 2014-02-06
JP5739908B2 JP5739908B2 (ja) 2015-06-24

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546185A Expired - Fee Related JP5739908B2 (ja) 2009-12-23 2010-12-22 血管形成関連の眼疾患の処置のための組成物および方法

Country Status (14)

Country Link
US (1) US9044436B2 (enExample)
EP (1) EP2515926A4 (enExample)
JP (1) JP5739908B2 (enExample)
KR (1) KR20120130752A (enExample)
CN (1) CN102883738A (enExample)
AR (1) AR079706A1 (enExample)
AU (1) AU2010336475A1 (enExample)
BR (1) BR112012015188A8 (enExample)
CA (1) CA2782796A1 (enExample)
MX (1) MX2012007416A (enExample)
NZ (1) NZ600544A (enExample)
RU (1) RU2012131251A (enExample)
TW (1) TWI581801B (enExample)
WO (1) WO2011079175A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
EP3182988A4 (en) * 2014-08-22 2018-05-23 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
ES2836426T3 (es) * 2014-12-31 2021-06-25 Huons Co Ltd Composición, que contiene péptido que contiene motivo RGD o fragmento de éste, para aliviar las arrugas de la piel
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20250021281A (ko) 2023-08-04 2025-02-12 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물
CN121666229A (zh) 2023-08-04 2026-03-13 (株)来时协乐 包含i型胶原蛋白和色素上皮衍生因子肽作为活性成分的、用于预防或治疗新生血管性眼病的滴眼液组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
AU2002339862A1 (en) * 2001-09-04 2003-05-26 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
EP1534718A4 (en) 2002-06-07 2006-06-07 Wisconsin Alumni Res Found CHEMICAL SYNTHESIS OF REAGENTS FOR PEPTIDE COUPLING
US20070025957A1 (en) * 2005-04-29 2007-02-01 Rosenblum Michael G Vascular targeting of ocular neovascularization
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
NZ597580A (en) * 2009-07-20 2013-11-29 Univ Nat Taiwan Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof

Similar Documents

Publication Publication Date Title
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
JP2015526467A5 (enExample)
JP2012525415A5 (enExample)
JP2022512478A5 (enExample)
KR20200140830A (ko) 에피네프린 스프레이 제제
US12208091B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2016506391A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
JP2015528454A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2020090547A (ja) 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2017531044A5 (enExample)
US9827220B2 (en) Treatment for ischemic stroke
CN106413708A (zh) Nmda受体拮抗剂的医药用途及其药物组合物
CA3022152C (en) DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TOPICAL OCULAR TREATMENT OF RETINAL NEURODEGENERATIVE DISEASES
JP2009506978A5 (enExample)
JP2016515137A5 (enExample)
JP2016505050A5 (enExample)
FI3590960T3 (fi) Perifeeristen hermojen IgG-stimuloitu remyelinaatio
JP2009519962A5 (enExample)
JP2019507786A5 (enExample)
RU2014126070A (ru) Способы лечения и предотвращения глазных заболеваний
US20240366729A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
WO2021005147A1 (en) Combination
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合